AVLN

AVLN remains in a strong parabolic uptrend with EMAs aligned. The recent pullback into the rising 9-EMA has held support, offering a clean tactical entry. However, RSI remains in extreme overbought territory, signaling caution for potential deeper retracements toward the 20-EMA. As long as price holds above the rising EMAs, the medium-term bias stays bullish. A decisive break and close below the 20-EMA on increased volume would invalidate the bullish stance.

• ↑Completed enrollment in Phase 2b MIST trial, advancing AP01/AP02 clinical progress.
• ↑Raised $316.6M in May 2026 IPO; Q2 cash position at $413M.
• ↓Q2 net loss rose to $28.9M from $20.2M YoY, underscoring cash burn.